Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1049) 1049
science & technology (879) 879
life sciences & biomedicine (814) 814
female (737) 737
bridged-ring compounds - therapeutic use (644) 644
middle aged (483) 483
oncology (472) 472
adult (407) 407
aged (404) 404
male (388) 388
antineoplastic combined chemotherapy protocols - therapeutic use (380) 380
animals (378) 378
bridged-ring compounds - administration & dosage (371) 371
breast neoplasms - drug therapy (339) 339
taxoids - therapeutic use (324) 324
chemotherapy (287) 287
bridged-ring compounds - pharmacology (286) 286
taxoids - administration & dosage (283) 283
biological and medical sciences (276) 276
medical sciences (261) 261
antineoplastic agents - therapeutic use (240) 240
treatment outcome (238) 238
cancer (237) 237
breast cancer (224) 224
breast neoplasms - pathology (202) 202
pharmacology & pharmacy (190) 190
mice (176) 176
pharmacology. drug treatments (161) 161
tumors (159) 159
taxoids (139) 139
retrospective studies (134) 134
rats (128) 128
disease-free survival (125) 125
neoplasm staging (125) 125
prognosis (123) 123
aged, 80 and over (121) 121
bridged-ring compounds - adverse effects (120) 120
antineoplastic agents (119) 119
bridged-ring compounds - chemistry (118) 118
care and treatment (114) 114
chemotherapy, adjuvant (109) 109
drug resistance, neoplasm (109) 109
analysis (108) 108
research (107) 107
anthracyclines - therapeutic use (103) 103
bridged bicyclo compounds - therapeutic use (101) 101
taxane (101) 101
medicine & public health (98) 98
deoxycytidine - analogs & derivatives (96) 96
ovarian neoplasms - drug therapy (93) 93
taxoids - adverse effects (93) 93
anthracyclines - administration & dosage (92) 92
neoadjuvant therapy (92) 92
dose-response relationship, drug (91) 91
antineoplastic combined chemotherapy protocols - adverse effects (90) 90
survival rate (88) 88
clinical trials as topic (87) 87
gynecology. andrology. obstetrics (84) 84
neoplasm metastasis (84) 84
taxoids - pharmacology (79) 79
cell line, tumor (78) 78
hematology, oncology and palliative medicine (77) 77
survival analysis (77) 77
monoterpenes (75) 75
abridged index medicus (74) 74
metastasis (74) 74
time factors (74) 74
drug administration schedule (73) 73
antineoplastic agents - pharmacology (69) 69
paclitaxel (69) 69
breast neoplasms - mortality (68) 68
deoxycytidine - administration & dosage (68) 68
health aspects (68) 68
lung neoplasms - drug therapy (68) 68
antineoplastic agents - adverse effects (67) 67
follow-up studies (65) 65
ovarian cancer (65) 65
breast neoplasms - metabolism (64) 64
chemistry (64) 64
fluorouracil - administration & dosage (63) 63
anthracyclines (62) 62
cisplatin - administration & dosage (62) 62
survival (61) 61
trastuzumab (61) 61
receptor, erbb-2 - metabolism (60) 60
taxanes (60) 60
mammary gland diseases (59) 59
cancer therapies (58) 58
drug therapy (57) 57
obstetrics & gynecology (57) 57
biochemistry & molecular biology (56) 56
carcinoma, non-small-cell lung - drug therapy (55) 55
chemistry, medicinal (55) 55
ramipril (55) 55
docetaxel (54) 54
antineoplastic agents - administration & dosage (53) 53
physical sciences (52) 52
disease models, animal (51) 51
bridged-ring compounds - chemical synthesis (50) 50
young adult (50) 50
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1241) 1241
Japanese (48) 48
Russian (26) 26
Chinese (23) 23
German (17) 17
Italian (14) 14
French (12) 12
Spanish (3) 3
Bulgarian (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
by Pivot, X and Marmé, F and Koenigsberg, R and Guo, M and Berrak, E and Wolfer, A
Annals of oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1525 - 1531
clinical trial | triple-negative breast cancer | pooled analysis | metastatic breast cancer | eribulin | survival | Clinical trial | Metastatic breast cancer | Eribulin | Pooled analysis | Survival | Triple-negative breast cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Anthracyclines - adverse effects | Adjuvants, Pharmaceutic | Receptor, ErbB-2 - genetics | Humans | Antineoplastic Agents - therapeutic use | Furans - adverse effects | Triple Negative Breast Neoplasms - drug therapy | Furans - therapeutic use | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Clinical Trials, Phase III as Topic | Neoplasm Metastasis | Triple Negative Breast Neoplasms - genetics | Antineoplastic Agents - adverse effects | Triple Negative Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Female | Ketones - therapeutic use | Receptor, ErbB-2 - antagonists & inhibitors | Anthracyclines - therapeutic use | Bridged-Ring Compounds - administration & dosage | Ketones - adverse effects | Taxoids - adverse effects | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
by Loibl, S and Weber, K E and Timms, K M and Elkin, E P and Hahnen, E and Fasching, P A and Lederer, B and Denkert, C and Schneeweiss, A and Braun, S and Salat, C T and Rezai, M and Blohmer, J U and Zahm, D M and Jackisch, C and Gerber, B and Klare, P and Kümmel, S and Schem, C and Paepke, S and Schmutzler, R and Rhiem, K and Penn, S and Reid, J and Nekljudova, V and Hartman, A -R and von Minckwitz, G and Untch, M and Arbeitsgemeinschaft Gynakologische and GBG
Annals of oncology, ISSN 0923-7534, 12/2018, Volume 29, Issue 12, pp. 2341 - 2347
Neoadjuvant chemotherapy | Carboplatin | Homologuous recombinant deficiency | Survival | Triple-negative breast cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Paclitaxel - pharmacology | Prognosis | Taxoids - pharmacology | Follow-Up Studies | Breast - surgery | Humans | Middle Aged | Polyethylene Glycols - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Taxoids - therapeutic use | Carboplatin - therapeutic use | Anthracyclines - pharmacology | Bridged-Ring Compounds - pharmacology | Doxorubicin - analogs & derivatives | Triple Negative Breast Neoplasms - pathology | Mastectomy | Female | Breast - pathology | Polyethylene Glycols - pharmacology | Bridged-Ring Compounds - therapeutic use | Recombinational DNA Repair - genetics | Triple Negative Breast Neoplasms - mortality | Paclitaxel - therapeutic use | Triple Negative Breast Neoplasms - therapy | BRCA1 Protein - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Triple Negative Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | Survival Analysis | Anthracyclines - therapeutic use | Mutation | Carboplatin - pharmacology | BRCA2 Protein - genetics | Doxorubicin - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis
by Doheny, Daniel and Sirkisoon, Sherona and Carpenter, Richard L and Aguayo, Noah Reeve and Regua, Angelina T and Anguelov, Marlyn and Manore, Sara G and Arrigo, Austin and Jalboush, Sara Abu and Wong, Grace L and Yu, Yang and Wagner, Calvin J and Chan, Michael and Ruiz, Jimmy and Thomas, Alexandra and Strowd, Roy and Lin, Jiayuh and Lo, Hui-Wen
Oncogene, ISSN 0950-9232, 10/2020, Volume 39, Issue 42, pp. 6589 - 6605
Biochemistry & Molecular Biology | Oncology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Anilides - therapeutic use | Pyrazoles - therapeutic use | Alternative Splicing | Zinc Finger Protein GLI1 - metabolism | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Drug Resistance, Neoplasm | Smoothened Receptor - metabolism | Triple Negative Breast Neoplasms - drug therapy | Biphenyl Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Biphenyl Compounds - pharmacology | Neoplasm Metastasis - drug therapy | Janus Kinase 2 - metabolism | Bridged-Ring Compounds - pharmacology | Triple Negative Breast Neoplasms - pathology | Neoplastic Stem Cells - pathology | Female | Trastuzumab - pharmacology | Smoothened Receptor - antagonists & inhibitors | Janus Kinase 2 - antagonists & inhibitors | STAT3 Transcription Factor - metabolism | Pyrazoles - pharmacology | Pyridines - therapeutic use | Bridged-Ring Compounds - therapeutic use | Trastuzumab - therapeutic use | Zinc Finger Protein GLI1 - genetics | Pyrimidines - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Anilides - pharmacology | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Antimitotic agents | Prognosis | Growth | Stem cells | Breast cancer | Metastasis | Antineoplastic agents | Vascular endothelial growth factor | Toxicity | Lung cancer | Stat3 protein | Stem cell transplantation | Cancer therapies | ErbB-2 protein | Metastases | Medical prognosis | Janus kinase 2 | Xenografts | Trastuzumab | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
by Rahma, O.E and Duffy, A and Liewehr, D.J and Steinberg, S.M and Greten, T.F
Annals of oncology, ISSN 0923-7534, 08/2013, Volume 24, Issue 8, pp. 1972 - 1979
treatment | pancreatic | cancer | second-line | analysis | review | Second-line | Treatment | Review | Analysis | Pancreatic | Cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Pharmacology. Drug treatments | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Erlotinib Hydrochloride | Bridged-Ring Compounds - therapeutic use | Humans | Survival | Pancreatic Neoplasms - drug therapy | Platinum Compounds - therapeutic use | Disease-Free Survival | Fluorouracil - therapeutic use | Taxoids - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Deoxycytidine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Pancreatic Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Index Medicus | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
by Thuss-Patience, Peter C, MD and Shah, Manish A, MD and Ohtsu, Atsushi, MD and Van Cutsem, Eric, Prof and Ajani, Jaffer A, Prof and Castro, Hugo, MD and Mansoor, Wasat, PhD and Chung, Hyun Cheol, Prof and Bodoky, Gyorgy, Prof and Shitara, Kohei, MD and Phillips, Gail D Lewis, MS and van der Horst, Tina, MSc and Harle-Yge, Marie-Laurence, MSc and Althaus, Betsy L, PharmD and Kang, Yoon-Koo, Prof
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Current Systemic Therapies for Melanoma
by Palathinkal, Darren M and Sharma, Timmie R and Koon, Henry B and Bordeaux, Jeremy S
Dermatologic surgery, ISSN 1076-0512, 09/2014, Volume 40, Issue 9, pp. 948 - 963
Life Sciences & Biomedicine | Dermatology | Surgery | Science & Technology | Skin Neoplasms - drug therapy | Dacarbazine - therapeutic use | Interleukin-2 - adverse effects | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Interleukin-2 - therapeutic use | Oximes - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Platinum Compounds - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Imidazoles - therapeutic use | Skin Neoplasms - pathology | Bridged-Ring Compounds - therapeutic use | Pyrimidinones - therapeutic use | Interferon-alpha - therapeutic use | Antineoplastic Agents - economics | Melanoma - secondary | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Indoles - therapeutic use | Interferon-alpha - adverse effects | Pyridones - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
by Perez, Edith A, Dr and Awada, Ahmad, MD and O'Shaughnessy, Joyce, MD and Rugo, Hope S, MD and Twelves, Chris, MD and Im, Seock-Ah, MD and Gómez-Pardo, Patricia, MD and Schwartzberg, Lee S, MD and Diéras, Veronique, MD and Yardley, Denise A, MD and Potter, David A, MD and Mailliez, Audrey, MD and Moreno-Aspitia, Alvaro, MD and Ahn, Jin-Seok, MD and Zhao, Carol, MS and Hoch, Ute, PhD and Tagliaferri, Mary, MD and Hannah, Alison L, MD and Cortes, Javier, MD
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1556 - 1568
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Bridged-Ring Compounds - therapeutic use | Physicians | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Antibiotics, Antineoplastic | Capecitabine - therapeutic use | Breast Neoplasms - drug therapy | Polyethylene Glycols - therapeutic use | Taxoids - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Anthracyclines - therapeutic use | Neoplasm Staging | Medical colleges | Care and treatment | Anthracyclines | Breast cancer | Product development | Metabolites | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Screening for the efficacy on lipid accumulation in 3T3-L1 cells is an effective tool for the identification of new anti-diabetic compounds
by Zeng, Xiao-Yi and Zhou, Xiu and Xu, Jun and Chan, Stanley M.H and Xue, Charlie L and Molero, Juan C and Ye, Ji-Ming
Biochemical pharmacology, ISSN 0006-2952, 09/2012, Volume 84, Issue 6, pp. 830 - 837
Obesity | Lipid accumulation | Insulin resistance | Fatty liver | Drug discovery | Phenotypic screening | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Glucose Intolerance - metabolism | Quinolizines - therapeutic use | Drugs, Chinese Herbal - pharmacology | Male | Anti-Obesity Agents - therapeutic use | Glucose Intolerance - drug therapy | Bridged-Ring Compounds - chemistry | Bridged-Ring Compounds - pharmacology | Dietary Fats - administration & dosage | Drugs, Chinese Herbal - therapeutic use | Hypoglycemic Agents - therapeutic use | Cell Line | Drug Evaluation, Preclinical - methods | Bridged-Ring Compounds - therapeutic use | Adiposity - drug effects | Alkaloids - pharmacology | Fatty Liver - metabolism | Mice, Inbred C57BL | Insulin Resistance | Hypoglycemic Agents - chemistry | Quinolizines - pharmacology | 3T3-L1 Cells | Fatty Liver - drug therapy | Hypoglycemic Agents - pharmacology | Triglycerides - metabolism | Anti-Obesity Agents - chemistry | Animals | High-Throughput Screening Assays | Drugs, Chinese Herbal - chemistry | Lipid Metabolism - drug effects | Alkaloids - therapeutic use | Mice | Anti-Obesity Agents - pharmacology | Alkaloids - chemistry | Fructose - administration & dosage | Quinolizines - chemistry | Type 2 diabetes | Synthesis | Hydroxides | Blood sugar monitoring | Triglycerides | Medicine, Chinese | Glucose | Fatty acids | Glucose tolerance tests | Dextrose | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Metastatic melanoma: Chemotherapy
by Bajetta, Emilio and Del Vecchio, Michele and Bernard-Marty, Chantal and Vitali, Milena and Buzzoni, Roberto and Rixe, Olivier and Nova, Paola and Aglione, Stefania and Taillibert, Sophie and Khayat, David
Seminars in oncology, ISSN 0093-7754, 10/2002, Volume 29, Issue 5, pp. 427 - 445
Life Sciences & Biomedicine | Oncology | Science & Technology | Cytokines - therapeutic use | Bridged-Ring Compounds - therapeutic use | Immunotherapy - methods | Nitrosourea Compounds - therapeutic use | Dacarbazine - therapeutic use | Humans | Interferon-alpha - therapeutic use | Interleukin-2 - therapeutic use | Organophosphorus Compounds - therapeutic use | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Paclitaxel - therapeutic use | Melanoma - secondary | Carboplatin - therapeutic use | Cisplatin - therapeutic use | Taxoids | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Tamoxifen - therapeutic use | Thalidomide - therapeutic use | Genetic Therapy - methods
Journal Article
Details down arrow